text:
Philippines' Digital Banking Framework to Trigger Wave of Innovation for the Unbanked
October 20, 2020 April 26, 2022 ByFintech Alliance.Ph Add Comment
In the Philippines, the upcoming digital banking framework will trigger a wave of innovation and help address financial exclusion, experts said.
During a recent webinar, experts representing CIMB Bank, RCBC, Finastra and Microsoft, discussed the forthcoming digital banking license, arguing that the entrance of new, tech-driven players will shake up the industry for the better.
Vijay Manoharan, CEO of CIMB Bank Philippines
"This is a positive move to welcome new players, specially tech players, who can bring in new ways of doing things in a more advanced way,"
Vijay Manoharan, CEO of CIMB Bank Philippines, said during the webinar.
"Overall, I expect this to improve the user experience and provide true, genuine value, as well as real access to banking and inclusion in a more affordable, and a more suitable way, long-term. This is a huge step forward. Customers will gain."
Leveraging technology, digital banks are able to reach segments that have so far been left behind, including those living in rural areas with no access to a banking branch.
The Philippines is home to more than 109 million people, making it the second most populous country in Southeast Asia behind Indonesia. But its archipelago geography formed of more than 7,000 islands is making it difficult with traditional banks to serve those located in the most remote places.
"Only 30% of adult Filipinos have access to a bank account," Manoharan said. "Traditional branch banking concept can't solve the [financial inclusion] problem in itself. The future has got to evolve and virtual banks have to be the solution."
The Bangko Sentral ng Pilipinas (BSP), the country's central bank, is aiming to increase to 70% the number of Filipino adults having formal bank accounts with basic deposit account BDA products within the next three years.
Shweta Jain, Director of Retail Banking Product at Finastra
Shweta Jain, director of retail banking product at Finastra, noted that rapidly rising Internet and mobile penetration rates were opening up new opportunities for incumbents and fintech companies.
"There is more than 100% mobile penetration in the Philippines and two thirds of Filipinos have access to the Internet, so taking mobile banking to them would be much faster than taking a branch or ATM to them,"
Jain said.
"70% of the population in the Philippines are unbanked. This digital banking license will really open the emerging market for financially excluded individuals and micro, small and medium-sized enterprises (MSMEs)."
Angelito Villanueva, EVP and Chief Innovation and Inclusion Officer at RCBC
The BSP is planning to issue later this month a new circular on the establishment of digital banks. The upcoming licensing framework is the latest initiative from the BSP and follows previous moves to promote innovation in the banking sector, Angelito Villanueva, EVP and chief innovation and inclusion officer at RCBC, said.
"This is a very welcome move, especially during the pandemic,"
"The BSP has been very dynamic and very active in promoting innovation in the financial ecosystem."
Basudev Banerjee, Industry Executive for Financial Services at Microsoft Asia Pacific
For Basudev Banerjee, industry executive for financial services at Microsoft Asia Pacific, this new regulation will further push incumbents to innovate.
"It's not only for the unbanked, but technology is also helping banks grow their businesses,"
Banerjee said.
"Traditional banks getting into digital banking model have big advantages. They know the market well, they know their customers well … and are [rapidly adopting APIs], opening their infrastructure."
But for fintech and digital banking to reach its full potential, several challenges must be addressed. For one, the needed physical infrastructure required for inclusion is still missing and poor Internet connectively, especially in rural areas, remains a major issue, Manoharan said.
"[Digital banking] is not a silver bullet and in one shot will solve everything overnight," Manoharan said. "It's going to be a journey to completely modernize the infrastructure, to revamp how banking is brought to Filipinos by leveraging technology."
In addition to this, more effort can be done on the regulatory front to facilitate onboarding.
"[Most financial excluded customers] don't have the formal data which allows them to open an account. Data like a passport or national ID or a driver's license," said Jain. "This is where the BSP would need to step in and create those opportunities or initiatives to help banks open account for them."
Bank exec cites lesser need for physical branches
Digitization not just for coping; embracing it is the way forward


To say there is a lot of buzz around the launch of Max for Live is something of an understatement. It's done nothing short of send Live-loving music geeks into a frenzy around the potential for new ways of processing audio and connecting technologies. This last point is what I'm interested in, and seeing as I'm doing a lot of chatter around OSC for my Sound Media 2 / Advanced Multimedia Authoring project, I thought I should take a quick look at what Max for Live means for anyone else dealing with OSC.
MaxMSP and its (less attractive, but nonetheless charming) open source cousin PureData both allow for custom routing of not just audio signals, but a wider range of protocols. MIDI has been hanging around for a long time now, and it's ability to communicate a large amount of data is pretty poor. This is why we're now looking to protocols like OSC to deal with higher bandwidth inputs.
When I began working on my data[origin] project, I did take a look at the ability to tap into the LiveAPI via Python script, but pretty quickly I realised that with my limited knowledge of code, I was going to spend more time trying to understand it than moving forward. In the end I converted OSC to MIDI, which has it's own set of problems but was a little bit more entry-level friendly. The addition of Max for Live will basically make OSC natively available within the Ableton environment.
In addition to the routing power of Max, there will also be live visual capabilities in the form of MaxMSP's sister software, Jitter. This makes the package more exciting to me, because it will mean that much more can be done directly out of the single Ableton environment. It also makes the US$299 price tag (for owners of Live 8 – more confusing if you're not an owner) a little more palatable.
Of course, if you're just a music producer, Max may not offer you enough to justify the high price tag. I think it's a more interesting prospect for those looking to extend live performance from the laptop to allow inputs from weird and wonderful controllers and output to screens, lighting, or really anywhere that your imagination takes you. If you're a Live 8 user, you can download the public beta of Max for Live. I'm doing just that and will report back with my experience over the next couple of weeks.


text:
Larry and Tammy Allred
Pastor Larry Allred is the founding pastor of North Merida Baptist Church in Merida, Mexico. He and his wife have served there for over twenty years. Find out more on his website here.
Jason and Ellen Thomas
Pastor Jason Thomas is the pastor of a church in Parral, Chihuahua, Mexico. Find out more on the Baptist Missions to Forgotten Peoples' website here.
Dr. Eddie Wang
Dr. Eddie Wang is the director of Chinese for Christ International. Learn more about him and the organization under "Chinese for Christ International (CFCI)" on this page.
Christian Law Association
The Christian Law Association has been giving free legal assistance to churches and Christians since 1969. Learn more on their website here.
Christian Servicemen Center
The Christian Servicemen Center is a ministry of Northview Baptist Church in Fayetteville, North Carolina which was started by David Tremmel in 2013. Their goals are to reach the soldiers at Fort Bragg with the gospel and minister to them as they serve our country. Learn more here.
Pastor Derrick Morlan
Pastor Derrick Morlan is the pastor of Oxford Baptist Chapel in England. He is one of the missionaries with Central Missionary Clearinghouse. Learn more here.
Margaret Stringer
Margaret Stringer was a missionary to Paupa, Indonesia, for over forty years. She created a written form for the Citak's unwritten language and translated the Bible into both Citak and Tamnim. When she left, a crowd of 1,500 people went to the airport to beg her not to leave. Now, she is retired and speaks at churches and other events. She is the author of many books, including From Cannibalism to Christianity: The Vakabuis Story and Jesus Led Me All the Way: 40 Years in the Jungles of Paupa, Indonesia.
Dave Whitmore
Dave Whitmore has been a missionary to Brazil since 2004. He is with Fundamental Baptist Missions. Find out more about him on their website here.
Mshama and Martha Kinyonga
Mshama and Martha Kinyonga have been serving in Tanzania since 2013. They are with Fundamental Baptist Missions. Find out more about them here.
Segundo Mejia, Jr.
Segundo Mejia, Jr. serves in Calvary Baptist Church, Alaminos, Pangasinan, Philippines. Learn more here.
Jason Russell is a missionary to Papua New Guinea. Learn about him here.
Dr. Wayne Sehmish
Dr. Wayne Sehmish is a missionary to Thailand. Watch the below video and visit the Thailand Ministries website to learn more.
Bro. Dennis Thomas
Bro. Dennis Thomas and his wife Jolaine have been missionaries for over 40 years. Currently, they serve in Latin America. Learn more here.
Macedonia Gospel Publications International
Macedonia Gospel Publications International makes tracks for churches and provides tracks to missionaries at no cost. Learn more here.
Pastor Wayne Randolph
Wayne Randolph is the pastor of New Manna Baptist Church in Covington, WA. He founded the church in 2016 after receiving the call to start a gospel preaching church in Washington. Learn more on their website here.
Pastor Manuel Gomez
Brother Manuel Gomez is a missionary to Michoacan, Mexico. When he visited Michoacan and saw the extreme poverty and that there was no one preaching the gospel there, the Lord put it on his heart to start a church. Now, through his ministry, he has started seven churches and a Bible institute.
The Holt Family
The Holts are missionaries to Chile. Through their ministry, Connect Chile, they have planted many churches and trained many pastors in their Bible college. Learn more on their website here.
The Whites are missionaries to Latin America. Through their ministry, they have planted four churches and a Bible institute. Learn more on their website here.
The Brown Family
The Browns are missionaries to West Africa. They planted Victory Baptist Church of Zinguedesse. Learn more here.
The Lees are missionaries to South Korea. Brother Young Ho Lee is the pastor of a church there. He is a missionary with Macedonia World Baptist Missions. Learn more here or view this page to read his prayer letters.
Pastor Gordon Horton
Brother Gordon Horton is the pastor of Community Baptist Church of Durham in Hampton, Ontario, Canada. Learn more on the church's site here and on the Baptist Missions to Forgotten Peoples' website here.
Pastor Raleigh Hill
Pastor Raleigh Hill is the pastor of Freedom Baptist Church in Spirit Lake, Idaho. Learn more on the church's website here.
Victory Baptist Press
Victory Baptist Press began in 1984 and since then has sent out millions of Bibles and portions of scripture. Learn more on their website here.
Pastor Chris Rogers
Pastor Chris Rogers is the pastor of Harvest Baptist Church in Santa Fe, New Mexico. Learn more on their website here.
Church Location: 6401 Hog Mountain Road Bogart, GA 30622
Sunday School – 10:00 AM
Sunday Morning – 11:00 AM
Sunday Evening – 5:00 PM
Wednesday Evening – 7:00 PM

redpajama_set_name: RedPajamaCommonCrawl


The ability to manage business on the go is a must for just about all entrepreneurs. If you're a start-up bootstrapping with little or no money, there are many free or low-cost mobile apps to help you monitor employee productivity back at the office, stay connected to clients and meet project deadlines — all without being physically present at your base of operations.
1. Evernote for Business (evernote.com/business): An e-notebook platform for sharing content with colleagues, making presentations, and storing photos and documents in a secure, centralized online location. Cost: $10/user/month.
2. Uber (uber.com): This transportation network company connects passengers to professional drivers when riding and arriving in style is a must. Cost: Free to use app; must pay drivers' standard fares, which vary by city.
3. Dropbox for Business (dropbox.com/business): Never attach a file to email again thanks to this online file storage app.Cost: Free trial; $15/month subscription depending on desired storage capacity.
This content was brought to you by Business Accelerator. To access more free tools to grow your business dream, visit the business Accelerator, a virtual toolbox designed to inspire and help business owners and entrepreneurs build their businesses. This unique online experience features – articles, interviews, webcasts, podcasts and more… Your Dream Is Out There. Go Get It. We'll Protect It.


text:
Rapport COVID-19 DEW, propulsé par Reformulary® - Lire la suite
@var craft \craft\web\twig\variables\CraftVariableHeader
maDemande Connexion Conseiller Contact Lang Switcher EN
Accès Courtiers
COVID-19 DEW Report, powered by Reformulary®
Information about COVID-19 and the pharmaceutical industry's response changes by the hour. Here at Reformulary Group, our mission is to help Canadians make sense of medicine, and in times of crisis that is especially important. Our website will update on Wednesday of each week with the past several days' highlights of the medical community's attempts to tackle COVID-19.
Please note many of these drugs and technologies are in very early stages of development and the regulatory process. The information below is compiled for reference and personal interest only. The information is not complete and may not be accurate. Reformulary Group does not offer commercial or medical advice on these emerging developments. You should do your own investigation and seek your own professional advice before making any commercial or medical decision relating to this information.
Highlights of the medical community's attempts to tackle COVID-19.
Updated each Wednesday.
Coronavirus: Ontario announces funding for 15 research projects aimed at COVID-19
The Government of Ontario has announced $20 million in funding through the Ontario COVID-19 Rapid Research Fund towards 15 proposals. Projects focus on vaccine development, diagnostics and social sciences. One of the vaccine research projects, based at the University of Guelph, is trying to identify antibodies that can recognize the disease causing COVID-19 in mice and chickens and prevent its entry into their systems.
Dartmouth lab getting closer to developing COVID-19 vaccine
A biopharmaceutical company in Nova Scotia has made progress on developing a COVID-19 vaccine, hoping to start trials as soon as the summer. The company, IMV, has been aided by earlier work done on a vaccine for a serious respiratory condition that affects the elderly severely, much like COVID-19. An application to Health Canada for a trial involving 48 participants is being prepared.
Canadian researchers part of global effort to develop COVID-19 vaccine
A research team at the University of Saskatchewan, moving quickly towards testing a potential COVID-19 vaccine, has been boosted by the Government of Canada's recent announcement of significant financial support for the effort to find a vaccine. The team at VIDO-InterVac (Vaccine and Infectious Disease Organization – International Vaccine Centre) hopes to test its candidate on ferrets, an animal closely related to weasels with a respiratory system similar to humans, in the next month and is also planning additional animal testing on other researchers' vaccine candidates.
Health Canada issues warning against use of hydroxychloroquine for COVID-19
Health Canada has issued a warning against using hydroxychloroquine and chloroquine without the supervision of a medical professional. The warning comes from concern that people may be procuring the drugs to treat COVID-19 without consulting a doctor; a similar advisory was issued in the United States by the Food & Drug Administration (FDA). The drugs can cause a number of serious side effects including liver and kidney problems, dizziness, seizures and potentially fatal irregular heartbeat.
McGill Genome Centre to share in $20m funding for COVID-related DNA research
A new initiative, the Canadian COVID Genomics Network (CanCOGeN), will begin work sequencing the genomes of 10,000 Canadians who have been infected with COVID-19 to see if there are small differences that could explain disease severity in infected individuals.. The project will also track the genetic code of the COVID-19 virus itself, looking for small changes over time that can help to understand its severity and trajectory in Canada.
Algernon submits application to Health Canada for Ifenprodil COVID-19 phase 2b/3 multinational clinical trial
Algernon Pharmaceuticals has applied to Health Canada for a phase 2b/3 clinical trial of NP-120 (Ifenprodil), which is thought to have potential to reduce the infiltration of neutrophils and T-cells into the lungs. This could ultimately reduce the number of COVID-19 infected patients that progress to mechanical ventilation with intubation and to death. The application is designed such that a satisfactory result from a 100 participant phase 2b trial can result in immediately beginning a phase 3 trial without a new application.
Canadian company SaNOtize Research aims to limit COVID spread with nasal spray
A Vancouver-based company has announced Health Canada approval for a trial of a solution that releases nitric oxide, shown to have antiviral properties. The solution would be used as a gargle, nasal rinse and nasal spray. SaNOtize Research and Development Corp hopes to move quickly with the trial to determine if the spray can impede infection when deployed to the upper respiratory tract. If successful, the spray could have potential to protect frontline workers as well as the general population when physical distancing measures are eased.
U of T plays leading role in effort to develop COVID-19 treatment from recovered patients' blood plasma
A major Canadian study of blood plasma from recovered COVID-19 patients is moving ahead, including with a pediatrics component conducted by a professor and researcher at the University of Toronto and Sick Kids Hospital. The study, covered in an earlier edition of the COVID-19 DEW, is being led by researchers at McMaster, the University of Toronto and University of Montreal. It plans to recruit 1,200 adults and 100 children to determine if injections of plasma from recovered patients can help treat those who are fighting COVID-19.
U of T News
Ontario researchers developing COVID-19 vaccine delivered by nasal spray
Researchers at the University of Waterloo are working on a nasal spray that will serve the dual purposes of vaccinating against COVID-19 and treating it in people who are already infected. It works by producing a virus-like particle (VLP) that stimulates an immune response to SARS-CoV-2, the virus responsible for COVID-19. It also binds to receptors commonly used by the virus, giving it fewer entry points to latch onto. While there will be much testing ahead for the spray, researchers hope the pre-clinical work will be completed by April 2021. The project is a multi-disciplinary effort involving three teams from the university.
Alberta testing anti-malaria drug as early COVID-19 treatment
Alberta is joining Quebec and New Brunswick in trialing hydroxychloroquine (PLAQUENIL®), a drug used to treat malaria, rheumatoid arthritis and lupus, in a study by the University of Alberta and University of Calgary. There has been considerable interest in the drug as a potential treatment for COVID-19 patients and trials in a number of jurisdictions, not all of them successful. Alberta's study seeks up to 1,660 adults at risk of developing severe COVID-19 to determine if a five-day course of hydroxychloroquine will lower hospitalization rates. Participants will be determined by Alberta Health Services.
Hamilton researchers move at 'lightning speed' to start trials for COVID-19 treatments
Researchers at McMaster University in Hamilton expect to soon be given Health Canada approval for a trial of COVID-19 treatments in at least 500 hospitalized and 1,000 non-hospitalized patients, with potential for the study to get quite a bit larger. Hospitalized patients will either get supportive care (the current method of treatment) or a combination of chloroquine and azithromycin (ZITHROMAX®); some hospitalized patients may also receive interferon-beta (AVONEX®), an immune modulating drug with antiviral potential. Patients not requiring hospitalization will receive supportive care or the drug combination.
McGill challenging the world to design an innovative ventilator
McGill University is in the latter stages of the Code Life Ventilator Challenge, a contest jointly organized with the Montreal General Hospital Foundation that calls on participants to submit a design for a cost-effective and easy to build and use ventilator. A number of partners, including ScotiaBank and the Canadian Medical Association, have stepped forward with $200,000 to be distributed as prize money and to support the administration of the contest. Over 1,000 entries were received, which are in the process of being judged by a volunteer team of subject experts primarily drawn from McGill's alumni network. An entry out of Queens University has advanced to the top 60, and final winners will be announced imminently.
McGill News
Pan-Canadian team launches covidtrials.ca to match patients with COVID-19 clinical trials
A Canadian healthcare technology company has launched a patient portal that aims to match on-going COVID-19 related trials to eligible participants. Interested people submit their relevant details through the secure portal, and if their profile matches the needs of a particular trial its organizers reach out. The team behind the portal located at https://covidtrials.ca/ feels it will fill an important need for researchers, who often struggle to fill studies with participants who meet requirements.
Health Canada approves new rapid COVID testing kits
Ottawa-based Spartan Bioscience has received federal approval for its rapid response portable COVID-19 test. The test ships in a coffee cup-sized portable DNA analyzer and includes the swabs that are necessary for testing. It is thought to be particularly important for remote communities and to administer the kind of rapid testing believed to be necessary for a return to 'new-normal' life. Test results are typically available in less than an hour. The company intends to make the product widely available to governments across Canada, with the federal government, Quebec, Alberta and Ontario already having made purchases.
Jewish General set to roll out game-changing app in COVID-19 battle
Jewish General Hospital in Montreal will be deploying a new smartphone app that monitors the user's vital signs to help screen for COVID-19 by having them simply stare into the phone's screen. The app will be used to identify arriving emergency room patients in need of isolation based on elevated heart rate and respiratory rate, as well as a low oxygen-saturation reading. It will also be used to monitor the vital signs of hospitalized patients and among the general population in parts of the city particularly hard-hit. While the app was designed in a Montreal-Tel Aviv partnership for broader use than just COVID-19 monitoring, the hospital has found it to be accurate and the Quebec government is considering a wider deployment.
WHO's SOLIDARITY trial lands in Canada, led by Sunnybrook Health Sciences Centre
Canadian hospitals will be participating in a global trial of various drugs and treatment options for COVID-19 patients that is being centrally coordinated by the World Health Organization (WHO). The trial will see lopinavir-ritonavir (KALETRA®), remdesivir, hydroxychloroquine (PLAQUENIL®) and chloroquine among the drugs that could be administered to patients. Sunnybrook Health Sciences Centre in Toronto has already begun enrolling patients, and up to 20 hospitals across Canada could ultimately participate.
Trial Site News
McGill University researchers looking for patients to test hydroxychloroquine as treatment for COVID-19
Following on the heels of New Brunswick, researchers at McGill University will begin a study on hydroxychloroquine, also known as PLAQUENIL®, as a potential treatment for COVID-19. The drug has been the subject of considerable discussion recently. Researchers are hopeful that the drug can reduce the likelihood of recently exposed people contracting the virus, and reduce the risk of complications from lung inflammation in those who have it. Adults in Quebec, Alberta or Manitoba who have tested positive for COVID-19 or had close exposure to a positive person are asked to consider enrolling.
Published: April , 20270
Canada begins clinical trial of experimental COVID-19 treatment using plasma from recovered individuals
A large trial using plasma, the liquid component of blood, will take place on Canadian soil, involving 1,000 patients and spanning more than 40 hospitals and some of the country's top universities across multiple provinces. The trial will involve taking antibody-rich plasma from people who have successfully recovered from COVID-19 and injecting it into patients currently fighting the virus. Recovered patients can provide plasma at blood donation centres across the country, and if it proves to be rich enough in antibodies it will be frozen and shipped to a participating hospital.
New Brunswick health networks collaborate on drug trial to treat people with COVID-19
New Brunswick's two health authorities are launching a study into the efficacy of hydroxychloroquine, also known as PLAQUENIL, to treat COVID-19. The Horizon Health Network and the Vitalité Health Network are in the process of designing study details. The drug has been the subject of a recent high profile discussion as a treatment for COVID-19, leading to a rare joint statement from a number of professional associations in Ontario warning about its use pending further study. Globally, there has been a divergence among countries over how to use hydroxychloroquine/chloroquine in the face of COVID-19.
New study from UBC researcher outlines pathway toward blocking COVID-19 virus
An international team based out of the University of British Columbia (UBC) has released findings suggesting a protein known as APN01 has potential to treat COVID-19 as an "antiviral therapy". This largely stems from its lab-observed ability to block the virus from binding itself to a cell wall and infecting human organs. Because work to date has been done on cells and engineered human tissue, there is a long road of testing and human trials ahead.
A look at the search for a COVID-19 vaccine in Canada
Researchers at various institutions spanning the country are working on different components of vaccine development, including building a vaccine bank, learning more about animal testing and examining the efficacy of previously known drugs to treat COVID-19.
Dalhousie research team prepares for clinical trial of COVID-19 vaccine
Dalhousie's COVID rapid response team believes it could be as little as three weeks away from beginning human trials on a potential COVID-19 vaccine. The team is working with a piece of the virus's DNA, different from more conventional influenza vaccines that use a protein piece. While the team is optimistic about the accelerated timeline to begin trials, they caution that vaccines still take a long time to develop and the most realistic hope for one to be released could be in time for a potential return of COVID-19 if it follows a seasonal pattern.
Montreal Heart Institute launches clinical study into potential COVID-19 treatment
Researchers in Montreal are rushing to launch a study into whether colchicine, an inexpensive anti-inflammatory drug most commonly used to treat gout, can reduce the risk of lung complications that characterizes the most serious COVID-19 cases. The trial seeks to recruit 6,000 adults 40 years of age or older, with half given a placebo (e.g. sugar pill) and half colchicine, and researchers are hopeful that some conclusions can be drawn in as little as 30 days.
Joint Statement on the Use of Hydroxychloroquine and Azithromycin for COVID-19 Prophylaxis
Professional associations representing doctors, pharmacists and nurses issued a rare joint statement urging caution to their members around unproven applications of hydroxychloroquine (PLAQUENIL®) and azithromycin (ZITHROMAX®) for COVID-19 treatments. The statement highlights a number of concerns about the two drugs being used in tandem, and notes an uptick in the drugs being prescribed jointly, something uncommon before COVID-19.
My RNAO
Quebec Company Partners with Government to Find a Cure
Medicago, a Quebec City-based company that successfully produced an H1N1 vaccine candidate in just 19 days, has partnered with the federal government as part of its effort to create a COVID-19 vaccine. The federal government has committed $192 million to the cause, of which Medicago will receive $7 million. The company has succeeded at creating a "virus like particle" and hopes to trial a vaccine in humans by summer 2020.
FDA gives okay for Moderna to advance coronavirus vaccine candidate mRNA-1273 to Phase II testing
Moderna has received United States Food & Drug Administration (FDA) approval to begin a phase 2 clinical trial of its mRNA-1273 COVID-19 vaccine candidate. The trial will enrol 600 participants. A phase I trial began in March under the National Institute of Health (NIH), and an application is being prepared for a phase 3 trial to commence in early summer.
First Word Pharma
French drugmaker to enrol thousands for coronavirus vaccine trials
Sanofi SA is partnering with industry rival GlaxoSmithKline Plc (GSK) to develop a COVID-19 vaccine candidate it believes could face clinical trials by September. Sanofi will contribute a protein antigen, a molecule that can help trigger an immune response, based off its influenza vaccine, while GSK will provide an approved adjuvant – a response-boosting agent – to increase antibodies and produce longer-lasting immunity. The plan is for an early stage phase I/II trial that enrols hundreds of participants in order to obtain more data than earlier trials typically provide, with hopes of late-stage trials with thousands of participants no later than early 2021.
A rundown of all COVID-19 vaccine developments can be viewed here.
Antiviral drug remdesivir shortens time to recover from pandemic virus, top US health official says
A large study enrolling 1,063 participants run by the United States' National Institute of Health (NIH) on Gilead Sciences' remdesivir shows COVID-19 patients taking the drug had recovery times improved by 31% (at 11 days, compared to 15 days for those receiving standard of care) leaving some, including Dr. Anthony Fauci, to believe it will soon become the country's standard of care for treating the disease. There was more interest in the results from this trial because it involved comparing the results against a control group receiving placebo, unlike some earlier remdesivir trials. The global view for remdesivir results was a bit more mixed, as a study out of China published by The Lancet showed no improvement in patient outcomes. However, Gilead and analysts suggested that the study was inconclusive to draw meaningful conclusions as it was terminated early due to insufficient participants.
Diagnostics firm says new Covid-19 test could be used 1 million times a week
Hologic, a Massachusetts-based diagnostic test manufacturer, believes it could create 1 million units per week of its new COVID-19 test, a development that if it materialized would dramatically increase the United States' testing capacity. The new tests run on a different version of existing COVID-19 testing technology and uses a proprietary technology. The company has applied for Emergency Use Authorization (EUA) for the product; until authorization is granted, it will be supplying it to labs governed by regulations that would allow its use prior to an EUA.
Arthritis drug shows early promise in severe COVID-19 cases study
A rheumatoid arthritis drug has shown potential to fight off the extreme inflammation that characterizes many severe COVID-19 cases in a clinical study out of France. Tocilizumab (ACTEMRA®) was used in a trial of 129 moderate to severe pneumonia patients, a known complication of COVID-19. While full results are not yet out, researchers involved in the study say that compared to a control group, those receiving the drug had a reduced number of deaths or life support interventions.
In race for a coronavirus vaccine, an Oxford group leaps ahead
A team from the Jenner Institute at Oxford University will be testing a COVID-19 vaccine candidate in more than 6000 people by the end of May, thanks to earlier vaccine development work on similar viruses including a coronavirus from last year. While many trials of potential COVID-19 vaccines start off with a few hundred participants, the Oxford team is moving forward at an accelerated pace after six rhesus monkeys who received their vaccine in the United States are healthy approximately a month after heavy exposure to COVID-19. The team believes that under the accelerated timeline, there is the possibility of a few million doses being available by September, far ahead of any other vaccine candidate currently being studied.
China's Sinovac amps up COVID-19 vaccine work with new facility backed by Chinese government
Chinese biotech firm Sinovac has obtained government assistance to finalize its push to produce up to 100 million units of COVID-19 vaccine per year if its candidate is successful. An $8.5 million low-interest loan will be used to construct a production facility, which will be repurposed for other vaccines if its COVID-19 candidate is unsuccessful.
Fierce Pharma
Did Gilead's remdesivir flop a Chinese trial? Analysts beg to differ
There is disagreement over media characterizations of leaked results of an aborted remdesivir trial in China. After the World Health Organization (WHO) inadvertently released data from a study that was suspended due to lack of participants, the Financial Times picked up the story and described the trial as a "flop." In the posted results, remdesivir was not associated with clinical or virological benefits. However, some analysts and remdesivir manufacturer Gilead Sciences point out that due to the small number of patients, the trial did not capture enough data to draw meaningful conclusions. As well, the manufacturer notes that better results were observed in patients treated early in their disease, although they did not provide data to support this statement.
Fierce Biotech
Lilly to start testing experimental drug in coronavirus patients soon
Eli Lilly hopes to begin human trials of an antibody treatment derived from the blood of recovered COVID-19 patients in the next month under a partnership with AbCellera Biologics. Eli Lilly will apply to the United States Food & Drug Administration (FDA) sometime in May and is prepared to move into a trial soon after approval. The company sees a potential antibody treatment as a bridging option until a vaccine is available.
Pfizer and new partner BioNTech nab approval to start closely watched COVID-19 vax test
Pfizer and BioNTech have been granted approval in Germany to begin a phase 1/2 trial of 4 mRNA COVID-19 vaccine candidates. Each candidate is a different format and targets different antigens. The trial will look for optimal dosing and study the effects of repeated immunization in 200 18- to 55- year old healthy subjects, and will test additional high-risk candidates in the second stage.
Hydroxychloroquine takes another hit in failed small scale COVID-19 study
A small-scale analysis of 368 severe COVID-19 patients treated in US Department of Veterans Affairs hospitals found no evidence of reduced risk of death or need for mechanical ventilation over supportive care among those treated with hydroxychloroquine, on its own or in combination with azithromycin (ZITHROMAX®). In fact, those patients given hydroxychloroquine on its own showed an increased risk for all-cause mortality. The study is one of many on-going around the world to determine the suitability of hydroxychloroquine and its analog chloroquine, two old anti-malaria drugs that have recently garnered attention in the search for a COVID-19 treatment.
Alexion, following clues from early tests, preps phase 3 study of Ultomoris in severe COVID-19
Alexion is beginning a global phase 3 trial of ULTOMIRIS® (ravulizumab-cwvz) that will involve about 270 patients with severe COVID-19 symptoms, including pneumonia and respiratory distress. By inhibiting the complement portion of a patient's immune system, it is thought that the drug can reduce lung inflammation, as well as lower cytokine and chemokine levels. Alexion has also considered further trials of SOLIRIS® (eculizumab) but opted for ULTOMIRIS®, a follow-up drug to SOLIRIS®, due to the less frequent dosing required and easier scaling of production.
Gilead's remdesivir looks promising in early leaked results, but don't jump to conclusions: analysts
COVID-19 patients at the University of Chicago Medical Centre have responded well to remdesivir, with most patients being discharged following decreasing fever and improved respiratory symptoms. The hospital is in the midst of two phase 3 trials involving 125 patients, including 113 severe cases. It's important to note that these results were shared by an infectious disease specialist at the hospital on a call with other staff, and were not publicly released; they do not represent full trial results. The Chicago study is one of several underway around the world to determine remdesivir's suitability as a COVID-19 treatment.
World's biggest trial of drugs to treat COVID-19 begins in UK
The world's largest trial of COVID-19 treatments is underway in the United Kingdom, with more than 5,000 patients enrolled representing 10% of all confirmed cases. The trial is starting with a number of repurposed drugs, including azithromycin (ZITHROMAX®), hydroxychloroquine, lopinavir-ritonavir (KALETRA®) and low-dose dexamethasone. The next drug to be added is an interleukin-6 antagonist, tocilizumab (Actemra), an immunomodulator used to treat inflammatory conditions. There is also discussion of including convalescent plasma. Because of the trial's size, each drug already has between 500 and 900 patients, plus a control group of 2,000.
Roche to launch COVID-19 antibody test by early May
Following Roche's launch of a test for active COVID-19 infections, the company has announced plans to release an antibody test for the virus next month. The Elecsys Anti-SARS-CoV-2 serology test will help identify people who have been infected with the disease, including those who may not have had any symptoms, and will be useful for return-to-work planning and modelling how widely it has infected a population. The technology has potential to provide results in 18 minutes and process up to 300 tests per hour.
J&J eyes 'imminent' coronavirus vaccine production, aims for a billion doses worldwide
Johnson & Johnson (J&J) has begun "at risk" manufacturing of its COVID-19 vaccine candidate, forecasting that it could produce as many as a billion units by the end of the first quarter of 2021. In this context, "at risk" means that the final design of the vaccine could change. J&J envisions a timeline where human trials could begin in September 2020, with emergency use approval to follow in early 2021. The company has partnered with US Department of Health and Human Services Biomedical Advanced Research and Development Authority (BARDA) to provide $1 billion in funding for vaccine production and has committed to produce its vaccine candidate on a non-profit basis.
Gilead shares slip as a second remdesivir COVID-19 trial is halted in China
Gilead Sciences has suffered what appears to be a setback in its efforts to test remdesivir as a potential treatment for COVID-19. In the past week two different trials, one for severe COVID-19 patients and another for mild to moderate ones, were suspended due to lack of participants. This follows some encouraging results from much smaller samples, including a 53 person study, and lab work at the University of Alberta.
Fujifilm speeds production of potential COVID-19 therapy Avigan
Japanese company Fujifilm is rapidly scaling production of its influenza drug AVIGAN® (favipiravir) to meet demand as a potential COVID-19 treatment. The drug was originally developed and approved for use as a treatment for novel and re-emerging influenza in the event an outbreak occurs, and has never been dispensed to the general public in Japan or internationally. It is currently subject to a number of trials in Japan and around the world.
China's CanSino Bio advances COVID-19 vaccine into phase 2 of preliminary safety data
China-based CanSino Bio has disclosed in financial regulation documents that it intends to move a COVID-19 vaccine candidate to a phase 2 clinical trial "soon." The development is lightning-quick by industry standards, as it has only been three weeks since the phase 1 trial concluded. Online enrolment is already available for this next phase. The trial will look at outcomes along three different timeframes: adverse reactions after 14 days; antibody levels after 28 days; and follow-up for up to six months.
Two-thirds of acute coronavirus patients tested on antiviral drug improved
An early study of remdesivir as a treatment for hospitalized COVID-19 patients yielded some encouraging results, as more than two-thirds (68%) saw an improvement. In total, outcomes for 53 individuals spanning North America, Europe and Japan were tracked following a 10-day compassionate use course of the drug. More than half of patients initially needing mechanical ventilation resumed breathing on their own, and almost half of all patients were discharged from hospital. Thirteen percent of patients died, and mortality was highest among those on a ventilator. Additional trials are required before broader conclusions about remdesivir's suitability as a COVID-19 treatment may be drawn.
The National Post
Samsung scores $362m deal to help Vir scale up COVID-19 antibody production
Vir Biotechnology and Samsung Biologics have agreed to a $362 million deal to scale up production of Vir's monoclonal antibody program to potentially treat COVID-19. Vir is currently focused on two possible antibodies, VIR-7831 and VIR-7832, aiming for phase 2 clinical trials in a matter of months. The company has signed a number deals in the past several months to boost production if treatment is shown to be effective.
Alexion plans phase 2 study of Soliris in COVID-19 in coming days: report
Alexion has announced plans to launch a Phase 2 trial of SOLIRIS® (eculizumab) to treat COVID-19 after some positive results in a smaller, ten patient proof-of-concept trial. The drug is currently used to treat a range of rare diseases related to the immune system, and researchers feel there is a rationale for testing it in COVID-19 patients. The trial is expected to start in a matter of days.
Roche accelerates another Actemra trial for COVID-19
Roche received a significant financial boost from the U.S. Biomedical Advanced Research and Development Authority (BARDA) to speed up the process of bringing ACTEMRA® (tocilizumab) to a phase 3 trial of COVID-19 patients. The $25 million grant is the next phase in the United States government's commitment to test the drug, following expedited Food and Drug Administration (FDA) approval to begin earlier trial phases. Currently used to treat rheumatoid arthritis, it is thought to have potential to reduce the lung inflammation that characterizes severe COVID-19 cases.
COVID-19 vaccine candidate shows potential, research shows
The University of Pittsburgh School of Medicine has developed a vaccine candidate that shows potential in trials with mice to neutralize the SARS-CoV-2, the coronavirus that causes COVID-19. The vaccine is delivered through a fingertip sized patch and researchers are in the process of obtaining regulatory approval to move into Phase 1 human trials.
Novartis, Incyte set to roll JAK inhibitor Jakavi into COVID-19 clinical trial
Novartis and their partner Incyte will be moving to a Phase 3 trial for JAKAVI® (ruxolitinib), testing whether or not it can reduce the lung complications that characterize most severe COVID-19 cases. The companies will also establish a compassionate use program for the drug, while protecting supplies for patients currently taking it for a range of inflammatory diseases and cancers.
BD to offer fingerstick antibody test for COVID-19
BD is preparing to offer a fingerstick test to detect antibodies that show an immune response to COVID-19, with results within 15 minutes. The test has potential to help rule out COVID-19 in patients as well as determine possible immunity to the virus in individuals who have had mild or no symptoms. The test should be available in the month of April and BD plans to produce up to a million units.
Gilead CEO says coronavirus hopeful remdesivir will be 'affordable' but it could still rake in revenue
Following widespread attention from reports of remdesivir showing potential to treat COVID-19 (covered in the March 31 COVID-19 DEW) Gilead Sciences CEO Daniel O'Day has committed to ensuring affordability and accessibility. In an open letter O'Day also outlined unprecedented amounts of remdesivir being made available through compassionate use programs and detailed plans moving forward to make that program more sustainable by focusing it on pregnant women and children while giving hospitals the option to make an application on behalf of critically ill patients. In Canada, remdesivir was previously available through Health Canada's Special Access Programme but due to volume of demand, Canadians are now encouraged to seek enrolment in a clinical trial.
Abbott receives FDA emergency use authorization for new COVID-19 test
The United States Food & Drug Administration (FDA) has given emergency use authorization to a COVID-19 test from Abbott that gives positive results in five minutes and negative results in 13 minutes. The test is portable, allowing for deployment as testing needs change and arise.
Treatment of 5 critically ill COVID-19 patients with convalescent plasma
A case series from Shenzhen, China that focused on five critically ill COVID-19 patients previously on ventilation found clinical improvements in all patients approximately one week after being treated with convalescent plasma from other patients who had successfully recovered from COVID-19. Improvements were seen in the form of body temperature normalization, decreases in viral loads related to COVID-19 and increases in neutralizing antibodies. Four patients no longer required respiratory support after plasma transfusion. Due to the small sample size and uncontrolled study design, further clinical trials are needed before drawing larger conclusions.
Remdesivir most promising COVID-19 drug, say researchers
A recently published survey of therapeutical developments related to COVID-19 suggests that the most effective treatments will prove to be those that target the SARS-CoV-2 virus responsible for COVID-19, namely remdesivir, which was developed by Gilead Sciences as a treatment for Ebola virus disease and Marburg virus infections, and tilarone. The review runs through more than 15 potential vaccines in development around the world and looks at other therapies just reaching the phase of trials in humans, such as blood transfusions between successfully recovered and critically ill patients. Here in Canada, while remdesivir was previously available under the Special Access Programme, that is no longer the case. Canadians are encouraged to seek access through clinical trials via Gilead Sciences.
FDA authorizes handheld COVID-19 test
Mesa Biotech's Accula device received emergency approval from the FDA. The company has a record of producing similar products for influenza testing, which can be administered at medical facilities and potentially give results in 30 minutes.
Top COVID-19 aspirants chloroquine, AbbVie's Kaletra and a flu drug disappoint in clinical tests
Chloroquine/ hydroxychloroquine, KALETRA® (lopinavir/ritonavir) and ARBIDOL (umifenovir) produced suboptimal results in various clinical trials performed in China, slowing hopes that one of the drugs could be re-purposed to treat COVID-19 patients. That said, the drugs are expected to continue being trialed moving forward, including in a major World Health Organization initiative expected to involve thousands of patients.
Roche launches clinical trial of COVID-19 pneumonia hopeful Actemra after backing from China.
An arthritis drug already included in the Chinese treatment guidelines for COVID-19 will soon face expanded testing in other countries, including the United States, to better establish its suitability before more widespread use. Beginning in early April, Roche's ACTEMRA® (tocilizumab) will be compared to placebo to treat patients with severe COVID-19 pneumonia, following up on widespread interest in it after its early March approval in China.
© 2020 Groupe Reformulary - Tous droits réservés
Confidentialité – Groupe Reformulary | Confidentialité – MédiGuide | Conditions


text:
Golden Globes Roasted for Shutting 'Minari' Out of Best Picture Race: 'Sad,' 'Racist,' 'Complete Bulls–'
Umberto Gonzalez
Nominations for the 2021 Golden Globes won't be announced until February, but the Hollywood Foreign Press Association (HFPA) is already under fire over rules that exclude Lee Isaac Chung's "Minari" from the Best Picture race.
As first reported by Variety, the A24 drama will be relegated to the Best Foreign Language Film category because it is primarily in Korean. A similar situation happened last year with Lulu Wang's "The Farewell," which was ineligible to compete in the Best Picture category at the Globes because of its mostly Mandarin dialogue.
The HFPA did not immediately return TheWrap's request for comment. The Golden Globe eligibility rule states that any film with at least 50% of non-English dialogue goes into the Foreign Language category. Because of this longstanding rule, "Minari" distributor A24 had no choice but to enter the film in the Best Foreign Language Film category in November.
Also Read: 'Minari' Film Review: Steven Yeun Leads Charming Drama About Korean Transplants in 1980s Arkansas
The initial report prompted a wave of outrage from film critics and from celebrities like Wang, Daniel Dae Kim and "Shang-Chi" star Simu Liu.
"Just for the record, 'Minari' is an American movie written and directed by an American filmmaker set in America with an American lead actor and produced by an American production company," Liu pointed out on Twitter.
Just for the record, Minari is an American movie written and directed by an American filmmaker set in America with an American lead actor and produced by an American production company 👀 https://t.co/6fbI7ppBPB
— Simu Liu (@SimuLiu) December 23, 2020
Kim tweeted "the film equivalent of being told to go back to your country when that country is actually America."
The film equivalent of being told to go back to your country when that country is actually America. https://t.co/kwEf8eO9v8
— Daniel Dae Kim (@danieldaekim) December 23, 2020
"I have not seen a more American film than 'Minari' this year," Wang, director of "The Farewell," said. "It's a story about an immigrant family, in America, pursuing the American dream. We really need to change these antiquated rules that characterizes American as only English-speaking."
I have not seen a more American film than #Minari this year. It's a story about an immigrant family, IN America, pursuing the American dream. We really need to change these antiquated rules that characterizes American as only English-speaking. https://t.co/1NZbkJFE9v
— Lulu Wang (@thumbelulu) December 23, 2020
In "Minari," Steven Yeun ("The Walking Dead") plays Jacob, the father of a group of Korean-American immigrants who find a new start in rural Arkansas in the 1980s. Chung wrote his period drama based on his own childhood growing up in the Midwest.
"Minari" won Sundance's top two prizes — the narrative feature jury prize and the audience award — when it premiered at the festival earlier this year.
Below, see more reactions to Wednesday's "Minari" news.
Checks "Inglorious Bastards" English to German, French & Italian ratio—-roughly 30:70 😐 #Minari is an American film. https://t.co/rO6bjpNHQO
— Harry Shum Jr (@HarryShumJr) December 23, 2020
Minari is the most/best American movie I saw this year. This is complete bullshit. https://t.co/Raufj2QtMG
— Angry Asian Man (@angryasianman) December 23, 2020
This is racist.
It was made by Americans.
It was shot and set in Arkansas. https://t.co/jt1NWcdTEP
— Hanna Ines Flint (@HannaFlint) December 23, 2020
MINARI is a beautiful film about coming to america in search of the american dream. it has a writer-director-producer and many cast members who are asian-americans. yet the only thing being noticed here is the asian part. the korean part. the otherized part. this is so wrong. https://t.co/5ZPwpopcZJ
— Alyse Whitney (@AlyseWhitney) December 23, 2020
Not surprising. As a 4th generation American of Asian descent I still have to explain to people that my books are not the same as Japanese manga. (Amulet is not even published in Japan) As long as you look a certain way, you will always be considered a visitor in your own home. https://t.co/dkdP8LOiYf
— Kazu Kibuishi (@boltcity) December 23, 2020
A sad and disappointing reminder that a movie about the American dream, set in America, starring an American, directed by an American, and produced by an American company, is somehow foreign. #Minari https://t.co/u8VVfp0Sf4
— Andrew Phung (@andrewphung) December 23, 2020
In case you don't think this is racist, Inglourious Basterds got a Golden Globe nom for Best Picture and is only ~30% in English https://t.co/Ptz4OEbxhR
— Jacob Oller (@JacobOller) December 23, 2020
Let us not forget that Inglorious Basterds was mostly not in English and was not classified the same way. https://t.co/HjMktWUV8F
— Franklin Leonard (@franklinleonard) December 23, 2020
Read original story Golden Globes Roasted for Shutting 'Minari' Out of Best Picture Race: 'Sad,' 'Racist,' 'Complete Bulls–' At TheWrap


Happy February everyone!!! The month of love and home to Valentine's Day, so you know what that means??? Pregnancy. So for this podcast in OBGYN month, we will discuss obstetrical laboratory screening: what do you order, when do you order it, what is absolutely required, what is available but not routinely ordered, and everything else you need to know when counseling pregnant patients.


Located in the historic Banker's Hill neighborhood, the Hangar 5 condo building was built in 2017 by Pujji Development and consists of 5 residential condos. Hangar 5 is an ultra modern and sleekly designed building that sits at Front Street with predominantly west and south facing views. The location is unsurpassed in the heart of Bankers Hill, close in proximity to Balboa Park, Downtown, beaches, airport, sailing, biking & so much more.
The architect, Nakhshab Development & Design Inc., created amazing spaces with soaring ceilings and sweeping walls of glass that open up to give the indoor-outdoor feeling to the living spaces. Hangar 5 offers an innovative approach to loft living in one of San Diego's most coveted urban locations. Five brand new private residences feature modern accents & vertical volume. Choose between single level or town-home-meets-loft style floor plans, each independently unique to fit every lifestyle.
There's also an amazing 3 bedroom 2 bath penthouse that features massive outdoor spaces that flow superfluously between the interior and exterior space. This penthouse features 1926 sq/ft of interior living space and has beautiful views of the San Diego Bay, Coronado and the Pacific Ocean.
Amenities at Hangar 5 include secured parking & storage, bicycle storage, a common area outdoor space with BBQ's & entertaining areas as well as an elevator that adds convenience to everyday life.
The condos at Hangar 5 went to market for sale in Spring of 2017 originally. Ultimately, they did not sell and the developer decided to rent the properties out. They came back to market in Spring of 2018 and are once again available for purchase.


The ultrasound technician, also called a Diagnostic Medical Sonographer, produces sonograms which are ultrasonic recordings. Using special imaging equipment, high frequency sounds waves are directed into the body to produce real-time or dynamic images of internal organs, the heart, the vascular system and fetuses to detect abnormalities. The MRI Technician does Magnetic Resonance Imaging, which uses radio waves and magnetism. Images are taken of patient organs, tissues, bones and joints using a specialized MRI machine that produces magnetic field and radio waves. The positions are similar but use different, sophisticated medical equipment.
How to Become an MRI Technician?
Earning certification as a Magnetic Resonance Imaging Technician through the American Registry of Radiologic Technologists (ARRT) is only possible by first completing a Magnetic Resonance Imaging training program that is ARRT recognized. After December 31, 2014, an Associates degree in sonography or Bachelors degree in sonography is required for eligibility to earn ARRT MRI certification. The degree does not have to be in radiologic science. Attending an ARRT recognized MRI technician school is important because it ensures students learn what is needed to meet ARRT's didactic and clinical competency requirements. The MRI technician program includes training in general patient care, MRI procedures, and quality control.
As of the May 2012 occupational employment and wages survey conducted by the federal government's Bureau of Labor Statistics, Diagnostic Medical Sonographers earned $65,860 as the median annual wages. That equates to $31.90 per hour. For the same time period, the MRI Technologist earned median annual wages of $65,360 or $31.42 per hour. The two positions are paid almost the same amount, making them very competitive positions. However, there were many more sonographers employed. The national estimate was 29,560 MRI Technologists versus 57,700 ultrasound technicians versus. Looking at projected job openings for the period 2012 to 2022, there are more employment opportunities in ultrasound technology 35,300 new positions than magnetic resonance imaging at 11,300 positions.
The MRI Technician and Ultrasound Technician do similar, but not identical, work. Both positions require critical thinking, specialized training, and the ability to work with a variety of people and patients. One of the major differences is the type of equipment used for taking MRIs versus sonograms. The MRI chamber often creates a lot of anxiousness in people who are already experiencing stress due to illness or disease. Ultrasound Technician use equipment that is much less stressful on patients. In addition, ultrasound technology is likely to offer greater employment opportunities in the future, because the equipment is more portable and the procedures are more affordable, benefiting the health care expansion effort.


text:
Home Find ZIPs in a Radius Printable Maps Shipping Calculator ZIP Code Database
Find ZIPs in a Radius
Search by ZIP, address, city, or county:
Please make sure you have panned and zoomed to the area that you would like to have printed using the map on the page. After it shows the area that you are interested in, select from the options below to print your map.
Alabama Alaska Arizona Arkansas California Colorado Connecticut Delaware Florida Georgia Hawaii Idaho Illinois Indiana Iowa Kansas Kentucky Louisiana Maine Maryland Massachusetts Michigan Minnesota Mississippi Missouri Montana Nebraska Nevada New Hampshire New Jersey New Mexico New York North Carolina North Dakota Ohio Oklahoma Oregon Pennsylvania Puerto Rico Rhode Island South Carolina South Dakota Tennessee Texas Utah Vermont Virginia Washington Washington, DC West Virginia Wisconsin Wyoming
Current View Only
Population Real Estate Employment Schools
Post Office City:
Forestville, PA (View All Cities)
ZIP Type:
PO Box (Reserve a PO Box)
Eastern (12:14am)
724 (Area Code Map)
41.2, -80.0
ZIP (~9 mile radius)
Cities in ZIP code 16035
The list below includes the cities that the US Post Office accepts for ZIP code 16035. The preferred city may not be the city in which the ZIP is located. The city for 16035 is usually the name of the main post office. When mailing your package or letter, always include the preferred or acceptable cities. Using any city in the list of unacceptable cities may result in delays.
Primary/preferred city:
Forestville, PA
Stats and Demographics for the 16035 ZIP Code
ZIP code 16035 is located in western Pennsylvania and covers a slightly less than average land area compared to other ZIP codes in the United States. It also has a slightly less than average population density.
The people living in ZIP code 16035 are primarily white. The number of middle aged adults is extremely large while the number of young adults is large. There are also a slightly higher than average number of single adults and a slightly less than average number of single parents. The percentage of children under 18 living in the 16035 ZIP code is slightly higher than average compared to other areas of the country.
218 people per sq mi
0.56 sq mi
Estimated Population over Time
Total Population by Age
Median Age: 40 Male Median Age: 34 Female Median Age: 42
Under 5 5-9 10-14 15-19 20-24 25-29 30-34 35-39 40-44 45-49 50-54 55-59 60-64 65-69 70-74 75-79 80-84 85 Plus
Male 5 3 7 5 7 2 2 1 2 5 6 5 6 1 0 2 0 0
Female 2 3 3 9 5 2 3 3 5 3 7 7 5 3 1 1 0 1
Total 7 6 10 14 12 4 5 4 7 8 13 12 11 4 1 3 0 1
Under 5 5 2 7
5-9 3 3 6
10-14 7 3 10
25-29 2 2 4
85 Plus 0 1 1
American Indian Or Alaskan Native
Other Race
Head of Household by Age
15-24 25-34 35-44 45-54 55-64 65-74 75-84 85 Plus
Owner 1 1 5 14 10 3 2 1
Renter 1 1 2 1 2 0 0 0
Total 2 2 7 15 12 3 2 1
Owner Renter Total
Families vs Singles
Husband Wife Family Households
Single Guardian
Singles With Roommate
Households with Kids
Average Household Size: 3
Households without Kids
Children by Age
Male 2 0 2 1 0 0 1 1 1 1 0 2 3 1 0 1 3 0 1 0
Female 0 1 0 1 0 0 1 1 1 0 1 0 2 0 2 1 1 1 4 1
Total 2 1 2 2 0 0 2 2 2 1 1 2 5 1 2 2 4 1 5 1
ZIP code 16035 has a small percentage of vacancies.
The majority of household are owned or have a mortgage. Homes in ZIP code 16035 were primarily built in 1939 or earlier. Looking at 16035 real estate data, the median home value of $82,000 is low compared to the rest of the country.
In Occupied Housing Units
Correctional Facility For Adults
Other Institutional
College Student Housing
Military Quarters
Other Noninstitutional
Year Housing was Built
Owned Households With A Mortgage
Owned Households Free & Clear
Renter Occupied Households
Households Vacant
Vacancy Reasons
Rented & Unoccupied
For Sale Only
Sold & Unoccupied
For Season Recreational Or Occasional Use
For Migrant Workers
Vacant For Other Reasons
Owner Occupied Home Values
Employment, Income, Earnings, and Work
The median household income of $67,500 is compared to the rest of the country.
As with most parts of the country, vehicles are the most common form of transportation to places of employment. Pedestrians and cyclists beware. The area has some of lowest percentages of commutes without a vehicle in the country. Compared to other ZIP codes in the country, 16035 has very few people that work at home. In most parts of the country, the majority of commuters get to work in under half an hour. However, that is not the case in 16035. It has a much lower than average number of people that make it to work in under half an hour. It is very uncommon, compared to the rest of the US, for employees to have to travel more than 45 minutes to their place of employment.
Worked Full-time with Earnings
Worked Part-time with Earnings
No Earnings
Average Household Income over Time
Annual Individual Earnings
Source of Earnings
Means Of Transportation To Work for Workers 16 and Over
Bicycle, Walked, or Other Means
Travel Time to Work (In Minutes)
Compared to other ZIPs, 16035 has a very small percentage of people that did not graduate high school. Compared to other ZIPs, a much higher percentage of the population has received a college degree.
Educational Attainment For The Population 25 Years And Over
Less than High School Diploma
Professional school degree
School Enrollment (Ages 3 to 17)
Enrolled in Public School
Enrolled in Private School
Not Enrolled in School
Harrisville, PA
Type: Standard
Slippery Rock, PA
Recent ZIP Searches
Zip Codes by State
Downloadable ZIP Code List
Data sources include the United States Postal Service, U.S. Census Bureau, Yahoo, Google, FedEx, and UPS.
© 2020 UnitedStatesZipCodes.org


Be with in a 2 hour drive of St. Louis Missouri.
Dues are $25.00 per year.
Be 21 years of age. 16 years of age if accompanied by a legal guardian.
Be able to obtain a C & R license.
Own your own re-enacting weapon.
Own the proper WWII uniform(s) and equipment required to do a correct impression.
Devote the time and money to achieve a quality, historically-accurate impression.
Facial hair will be trimmed to military standards.
Devote the time to research WWII by talking to Veterans and reading books to further your knowledge of the subject.
Fill out proper applications and submit it to the C.O.
Contact the C.O. if there are any question about these requirements.
Thank you for visiting, Public Welcome, Membership by Invitation only.


Small bird, up to 17 cm. Average weight 18 g. Plain olive-brown above, with white underparts tinged golden-orange. Has a pale eyebrow. Both sexes are similar. The species is more often heard than seen, but can be observed climbing reeds and other water vegetation. Makes short low flights across the water.
Breeding season: September to February. Clutch size is three to four. Builds a deep cup nest with a narrow top opening in amongst dense reeds. Made from dry reeds and other water plants woven together and lined with fine dry grass and feathers. Females incubate the eggs.
Not steaked like other grassbirds.
The Australian Reed-Warbler is sedentary in the north and migratory in the south, moving north to breed.
Found in dense vegetation alongside water, especially in thick reed beds, as well as tall crops and bamboo thickets.
A rich, melodious song, "twitchee-twitchee-twitchee-quarty-quarty-quarty". Also loud sharp "chat" and scolding calls.


text:
In rare rebuke, Conservative rabbis say the movement lacks leadership
(From the JTA)
By Joe Berkofsky size>
NEW YORK, Dec. 15 (JTA) — In unprecedented public criticism, Conservative rabbis are saying the movement is suffering from a crisis in leadership at a time of declining membership.
Charges that Conservative leaders have failed to map a clear path for the movement's future and that the movement's seminaries and professional bodies do not coordinate policy surfaced last week during a Rabbinical Assembly meeting called to discuss the National Jewish Population Survey 2000-01.
"As I speak to colleagues of mine, I don't have a sense that any of us really feel that there's a great global vision of where we are going as a movement," Rabbi Joshua Finkelstein, of Temple Emanuel of North Jersey in Patterson and Oakland, N.J., told JTA after the meeting.
Rabbi Jeffrey Wohlberg, of Washington's Adas Israel Congregation, agreed.
"We are in a period now where there is not one single vision for the movement, nor is there one person regarded as the only one articulating the movement's message," Wohlberg said.
Rabbi Ismar Schorsch, chancellor of the movement's flagship institution, the Jewish Theological Seminary, did not return calls seeking comment.
But Rabbi Joel Meyers, executive vice president of the Rabbinical Assembly, said such complaints have long dogged the centrist movement.
"Because of its diversity, the Conservative movement does not have a pointed ideology that one can, in two words, define the movement," Meyers said. "Not having a clear definition, the response is we don't have clear leadership."
But Wohlberg and Finkelstein's complaints, which echoed others expressed at the meeting, came not long after the latest Jewish population survey showed that the once-dominant centrist American Jewish denomination is losing many adherents.
While such criticism rarely has gone public, movement insiders say there have been rumblings for years about a lack of cohesion between the movement's congregational and rabbinical bodies and its main seminaries.
Then came the NJPS, which showed that only 33 percent of Jews who say they belong to a synagogue identify as Conservative. That's down from 38 percent a decade ago and from nearly 50 percent in the previous survey, in 1970.
Some scholars warn that the studies counted Jews differently and so direct comparisons may be misleading. But rabbis at Tuesday's meeting, which took place at JTS in New York, said the exact figures are less important than the larger questions the survey raised about Conservative Judaism.
"Instead of looking back at the last century, we should look forward to the new century," Finkelstein said. "NJPS just underscored the challenges that lie ahead of us."
Such calls were a reference to a recent remark last month by Schorsch in which he said it had been a "mistake" for the movement to sanction driving on Shabbat some four decades ago because the move had eroded the observance of Jewish law, or halachah, as some had warned at the time.
"Do we still discuss whether to ride to shul on Shabbat?" one participant wondered.
Rabbi Jerome Epstein, executive vice president of United Synagogue, the Conservative movement's congregational arm, acknowledged the growing malaise over leadership.
"What would be helpful in the movement is if we looked more strongly to the top and worked more in concert at the top to hash out policy decisions and to try to articulate them," Epstein said.
But Epstein and other Conservative leaders maintained that the movement's historical divisions over the extent of Jewish law one must follow signal a healthy, diverse movement.
"There is a difference between centrism and timidity," said Rabbi Bradley Shavit Artson, dean and vice president of the Ziegler School of Rabbinical Studies at the University of Judaism in Los Angeles.
"Our movement needs to continue to be bold in its advocacy for a dynamic halachah, and for a strong relationship with God and for an engagement with the world."
At the movement's most recent biennial in Dallas in October, Epstein repeated earlier calls for members to recommit to halachah. Epstein announced that he would form a commission of rabbis, educators, and lay people to spark new passion for "living the evolving halachah."
Referring to criticism about a vacuum at the movement's top, Epstein said, "We are trying to provide that leadership."
But the debate over whether the movement should focus on halachah or move in other directions continues to divide members.
Rabbi Michael Strassfeld, author of the Jewish Catalog series, Jewish primers that helped catalyze the independent-minded chavurah movement, said he holds a "counter-counterrevolutionary" theory that the Conservative leadership does signal a direction — "an emphasis that we need to take stands, or we're not going to be taken seriously."
But Strassfeld said halachah does not remain "the starting point" for most Conservative Jews. Instead, most are seeking "something of meaning and value" that could drive them to greater observance.
Whether or not the debate over halachah is driving Conservatives away, Epstein and Artson, among others, also have said that the movement's size relative to the Orthodox, Reform and Reconstructionist movements — all of which grew during the past decade — remains less important than the devotion of its core members.
"Conservative Judaism is still a very large presence and a very dynamic presence," Artson said. "I am not going to get into this sort of little boy war about whose is bigger."
Yet Meyers said he is concerned about the movement's numbers. Some people at the "margins" may be moving toward Orthodoxy, and assimilation and intermarriage may be pulling others toward the Reform movement or the secular world, Meyers said.
Part of the problem in counting Conservative Jews is that many resist being identified as such. They may belong to a Conservative chavurah or minyan but not consider themselves officially Conservative.
"There's an old joke in the movement, that when someone says they're 'just Jewish,' you say, 'I'm Conservative too,' " Meyers said.
Some at last week's meeting said the differences among denominations as revealed in the population survey auger well for Conservatives because they show greater attachment to Judaism among Conservative Jews.
Rela Mintz Geffen, president of Baltimore Hebrew University, said NJPS also showed that religion often plays a greater role in the lives of Conservative Jews than for Jews in the more liberal denominations.
For example, 81 percent of Orthodox Jews said religion was "very important" in their lives and 41 percent of Conservative Jews said so, compared with 24 percent of Reform Jews and 14 percent of secular Jews, she said.
Additionally, 72 percent of Orthodox said they "strongly agree" that they look to Judaism in making important life decisions, compared to 32 percent of Conservative respondents, 16 percent of Reform and 10 percent of secular Jews.
Mintz Geffen also cited the intermarriage rate compared with other denominations as a sign of the movement's strength.
While 47 percent of all Jews who married between 1996 and 2002 wed non-Jews, only 18 percent of those who identified as Conservative Jews did, and only 5 percent of Conservative synagogue-goers did — a gap she attributed to a lack of younger, marriage-age synagogue members.
"Even if all it is is that you call yourself Conservative, it makes a difference," Mintz Geffen said.
Others argued that despite the alleged leadership gap, elements of the Conservative movement are thriving — from the busy Camp Ramah system to booming Solomon Schechter Day Schools to growing seminary rolls.
But rabbis this week voiced a growing frustration that they do not know what, at least officially, comes next for the movement.
"There doesn't seem to be any direction for the movement, and we're yearning for one," said Rabbi Tsafi Lev, of the Pinebrook Jewish Center, in Montville, N.J.
← → Letting Your Wife Cut Your Hair is Shear Madness!


Promote your library with print materials and graphics designed to engage the customer. Go on, get noticed!
If you are looking for a quick way to advertise some popular eResources check out the following double-sided bookmarks. Each PDF prints 5 to an 8-1/2 x 11 sheet of paper and has a full color and an ink saver version. Ink Saver bookmarks have cutting guides.
Gale Databases – Order as is or customize. These materials are free but there is a limit to the amount you can order. You will need your library account code to access these materials.
Mango Languages – Download print-ready materials, digital images and communication templates. Can also customize and order a limited amount of free materials.
DayByDayNY – Download print-ready bookmarks to promote the NYS Family Literacy Calendar.
Summer Reading – Download print-ready materials and digital images.
OverDrive – Download print-ready materials, digital images and communication templates.
TumbleBooks – Download print-ready materials, digital images and letter to parents template.
E-Magazines / RBdigital – Download print-ready materials and digital images.
Looking for more? Access links to Do It Yourself [DIY] resources on the MHLS Marketing & Public Relations page under Getting the Word Out.
Use your website to spotlight specific databases or programs. Link the graphic for a streamlined customer experience.
To save images click the graphic then right click the open image and choose 'save as'.


text:
Q: Cygwin X applications do not launch I have a problem with Cygwin X, in that applications don't seem to run.
If I try to run gedit, or emacs, the applications seem to just return 0 immediately:
me@mycomputer ~
$ gedit &
[1] 10244

me@mycomputer ~
$ emacs &
[2] 10976
[1]   Done                    gedit

Similarly, if I try to start either of these applications from the X Applications Menu on the taskbar, they don't launch.
The Cygwin log file shows the following, indicating that the application started, and then exited straight away:
(xwin-xdg-menu:13896): GVFS-WARNING **: Error creating proxy: Error calling StartServiceByName for org.gtk.vfs.Daemon: Timeout was reached (g-io-error-quark, 24)

executing 'xterm -title '/home/mj3/.xsession-errors' -e less +F /home/mj3/.xsession-errors', pid 8080
(pid 8080 stderr) xterm: cannot load font "-Misc-Fixed-bold-R-*-*-13-120-75-75-C-120-ISO10646-1"
executing 'gapplication launch org.gnome.gedit', pid 9288
pid 9288 exited with status 0

Any ideas? It's driving me nuts! I've tried a fresh install of Cygwin, with the same results.

A: For the next guy with similar problem, the culprit was the anti virus Trend Micro OfficeScan.:
With AV disabled, everything seems to work fine.

http://www.cygwin.com/ml/cygwin/2018-07/msg00278.html

redpajama_set_name: RedPajamaStackExchange


text:
Milton Buzetto (ur. 14 listopada 1937 w Piracicaba, zm. 17 września 2018 tamże) – brazylijski piłkarz, grający na pozycji obrońcy, trener piłkarski.

Kariera piłkarska

Kariera klubowa
W 1956 rozpoczął karierę piłkarską w SE Palmeiras. Potem występował w klubach Noroeste, Bragantino i Juventus-SP, gdzie zakończył karierę w roku 1969.

Kariera trenerska
Karierę szkoleniowca rozpoczął w 1971 roku. Trenował kluby Juventus-SP, Corinthians Paulista, Guarani FC-SP, Goiás EC, Mixto (Cuiabá), Inter de Limeira, Athletico Paranaense, Maringá, Uberaba, Comercial (Campo Grande), Francana, XV de Piracicaba, União Barbarense, Taquaritinga, União (Rondonópolis MT), Paulista (Jundiaí), Vocem, Marcílio Dias i Jabaquara (Santos).

Sukcesy i odznaczenia

Sukcesy trenerskie
Juventus-SP
 zdobywca Troféu Paulo Machado de Carvalho: 1971
 mistrz Asahi International Soccer Tournament (Japonia): 1974
Mixto-MT
 mistrz Campeonato Matogrossense: 1979
Comercial-MS
 mistrz Campeonato Sul-Matogrossense: 1985

Przypisy

Bibliografia
 Profil na Footballzz
 Profil na Terceiro Tempo

Brazylijscy piłkarze
Brazylijscy trenerzy piłkarscy
Piłkarze Red Bull Bragantino
Piłkarze CA Juventus
Piłkarze EC Noroeste
Piłkarze SE Palmeiras
Trenerzy piłkarzy CA Bragantino
Trenerzy piłkarzy CA Juventus
Trenerzy piłkarzy Esporte Clube XV de Novembro (Piracicaba)
Trenerzy piłkarzy Goiás EC
Trenerzy piłkarzy Guarani FC
Trenerzy piłkarzy Paulisty FC
Trenerzy piłkarzy SE Palmeiras
Trenerzy piłkarzy SC Corinthians Paulista
Urodzeni w 1937
Zmarli w 2018
Ludzie urodzeni w Piracicabie

redpajama_set_name: RedPajamaWikipedia


text:
Bullyonline
The Need for Attention
Human beings are social creatures and need social interaction, positive feedback and validation of their worth, and many are happy with what attention they get naturally through their normal activities at home, at work or wherever they happen to spend their time. From time to time, people inevitably do things that might attract attention, but that is not their primary aim. In some situations it is quite normal to seek attention, such as in advertising, TV, radio and stage work and so on.
Some people need excessive attention and get it by behaving inappropriately. It could be due to lowered self-esteem, a lack of self-confidence, low levels of self-worth or self-love or feeling insecure. Some may seek positive attention by creating situations in which they hope to be praised, thanked or admired; Some perhaps are not bothered about the quality of attention they get, just so long as they get it, and so will elicit negative attention perhaps by making a scene in public, getting over-indignant about a trivial matter, causing heads to turn and tongues to wag. Some seek out sympathy by always having something to complain about. If you care for someone whose actions are plainly done to get others to take notice and react, it's important to consider what's motivating them. If it is a one-off, it might be a sign of tiredness or a reaction to pressures and stress. If the behaviour is persistent or goes beyond what one might normally expect, it can be a sign of an underlying mental health issue.
An article by Billi Gordon Ph.D in Psychology Today asserts that: "Excessive attention seeking is not a character flaw. It is a brain wiring response to early developmental trauma caused by neglect." The article goes on to describe attention-seeking in terms of brain function, with the conclusion that it cannot be fixed, but it can be managed.
"Internet Trolling" is a good example of persistent, abnormal behaviour. This is the often anonymous use of forums to post irrelevant, disruptive, insulting or abusive messages, designed to infuriate or upset members, leading to replies, counter criticism, and arguments and taking the forum way off topic. The troll gets a kick from single-handedly moving others to spend their time and emotional energy on him or her, and even on each other. The best way to deal with Internet trolling, and other adult behaviour which is primarily intended to elicit attention, is to not respond, to not engage and to thus deny the person the attention they seek. If the perpetrator is denied the attention, there's a chance that they will think twice before taking this approach again. If they get attention, they might well do it again.
Attention-seeking behaviour inevitably involves other people, who at best waste their time by becoming irritated by it, or they become an unwitting player in a fabricated melodrama. At worst, people can find that they have been manipulated, conned, harmed etc by it.
Tim Field made a link between some well documented forms of attention seeking behaviour and bullying because, he concluded, the manipulation, deceit, temper tantrums and "poor me" melodramas of attention seekers are also typical of adult bullies. Put another way, some forms of attention seeking behaviour also amount to bullying.
(This list is based on the original by Tim Field, but some inspiration from pages at http://mentalhealth.com has helped with the update.)
Persecutors
Histrionic Behaviour
Tends to have exaggerated, unpredictable emotional reactions to almost any incident, expressed over-dramatically or theatrically. Antagonistic and manipulative, using fear and guilt to motivate others. Uncomfortable when not the centre of attention. Inappropriately flirtatious, seductive and provocative; May also draw attention using physical appearance; Thinks relationships are more intimate than they are.
Narcissistic Behaviour
Feels superior, special, unique etc and needs to be admired; arrogant; exaggerates achievements and talents; preoccupied with ideas of success, power etc; has unreasonable expectations of favourable treatment. Callous: Takes advantage of others to achieve his or her ends; no recognition or consideration of others' feelings. Intolerant of criticism and defeat, responding with defiant counterattack. Relates to others in a significantly or extremely different way to average individuals in the same culture.
May exploit family, workplace or social club relationships, manipulating others with guilt and distorting perceptions. While there may be no physical harm involved, people are affected with emotional injury. Vulnerable family members are common targets. A common attention-seeking ploy is to claim he or she is being persecuted, victimised, excluded, isolated or ignored by another family member or group, perhaps insisting she is the target of a campaign of exclusion or harassment.
This pattern can be found in different contexts although where the alleged aggressor is the government / police / mental health service providers, or indeed "everyone", the person may be suffering from paranoid delusions. For the sake of this article on attention seeking, the attention-seeking manipulator can be presumed to not actually believe the claims of persecution they make, unlike the delusional person who sincerely and steadfastly believes them.
Factitious Disorder by Proxy
Difficult to detect, the documented condition Munchausen Syndrome By Proxy (MSBP, also known as Factitious Disorder By Proxy) involves a person intentionally causing harm to others, putting their life at risk, and then stepping in to save them and basking in the glory of having done so and being praised for their care, compassion and skill. It has been known to happen with mothers with responsibility for their children and nurses with responsibility for patients. Few observers realise the deaths and injuries are deliberate and the perpetrator may inadvertently kill several people before suspicions are aroused. When not in saviour mode, the perpetrator may be resentful or even contemptuous of those (s)he targets. A less destructive form of this behaviour pattern might involve deliberately breaking something and then stepping in to diagnose and repair the damage.
Rescuer
A "Rescuer" preys on people suffering misfortune, infirmity, illness, injury, or with any other perceived vulnerability, dashing in to "rescue" them from their suffering, and then basks in the praise and glory that follows. May exclude others from the act of rescue so as to be the singular focus of attention, and to help make the rescued person become dependent on them, which relationship can then be exploited with subsequent acts of rescue. When not in rescue mode, the perpetrator may be resentful, perhaps even contemptuous, of those (s)he targets.
May look like the one in charge, the person organising everything, the one who is reliable and dependable, the one to whom people can always turn. However, the objective is not to help, but to be the centre of attention.
There are a number of ways people play on others' emotions by making themselves appear is if they are getting a raw deal in life.
Victim Mentality
Distinctly different from someone who has sustained harm as a consequence of an actual incident, a person with victim mentality tends to perceive random events that have a negative effect on them as deliberate and targeted, and is defiantly unwilling to consider alternative explanations for the events or effects. He does not feel responsible for anything that is wrong with his life, but blames others for the same. She's aware of her rights but not of responsibilities, and places excessive expectation on others to solve their problems. When one problem is solved, another always follows.
False Victim
Intentionally creates situations in which it seems they are victimised, eg by sending hate mail to themselves, or damaging their own possessions in an attempt to incriminate a fellow employee, a family member, neighbour, etc. False victims can be calculating, cunning, devious, deceptive and manipulative, identifying the supposed perpetrator of the wrongdoing and producing plausible (but fabricated) evidence in support. The deception continues during any investigation where the false victim uses charm and cunning to plausibly dismiss any suggestion that they may be responsible. A background check may reveal that this is not the first time she has had this happen to her.
This might include feigning or exaggerating illness, playing on an injury, or perhaps causing or inviting injury, in extreme cases going as far as losing a limb. Severe cases may meet the diagnostic criteria for Munchausen Syndrome (also know as Factitious Disorder). The illness or injury becomes a vehicle for gaining sympathy and thus attention. The attention-seeker excels in manipulating people through their emotions, especially that of guilt. It's very difficult not to feel sorry for someone who relates a plausible tale of suffering in a "poor me" melodrama.
False Abusee
A person falsely claims they are the victim of abuse, sexual abuse, rape, bullying, etc as a way of gaining attention for themselves. Such crimes are difficult to prove at the best of times and their incidence is so common that falsely claiming to be an abusee appears like a simple, plausible way of getting sympathy and attention. A variation on this is to make the claim online, in Internet chat rooms and forums, where the facelessness and anonymity afforded by the Internet makes it easy for the attention seeker to say what they like without the prospect of any penalty. The alleged crime never gets reported to the authorities, for obvious reasons.
Feigner
When called to account and outwitted, the person instinctively uses the denial - counterattack - feigning victimhood strategy to manipulate everyone present, especially bystanders and those in authority. The most effective method of feigning victimhood is to burst into tears, for most people's instinct is to feel sorry for them, to put their arm round them or offer them a tissue. (See "histrionic behaviour", above). There's little more plausible than real tears, although as actresses know, it's possible to turn these on at will. Feigners are adept at using crocodile tears. From years of practice, attention-seekers often give an Oscar-winning performance in this respect. Feigning victimhood is a favourite tactic of bullies and harassers to evade accountability and sanction. When accused of bullying and harassment, the person immediately turns on the water works and claims they are the one being bullied or harassed - even though there's been no prior mention of being bullied or harassed. It's the fact that this claim appears only after and in response to having been called to account that is revealing.
False confessor
This person confesses to crimes they haven't committed in order to gain attention from the police and the media. In some cases people have confessed to being serial killers, even though they cannot provide any substantive evidence of their crimes. Often they will confess to crimes which have just been reported in the media. Some individuals are know to the police as serial confessors. The false confessor is different from a person who make a false confession and admits to a crime of which they are accused because of emotional pressure and inappropriate interrogation tactics.
Paranoiac
Some people wholeheartedly believe that they are being persecuted, spied upon, followed and being subjected to various forms of injustice by large numbers of others, including total strangers. This condition naturally leads to an inapropriate and unnatural level of defensiveness, which can culminate in profoundly harmful effects on others. An article in Pacific Standard Magazine examines the work of three University of British Columbia psychologists led by Donald Dutton, who analysed the writings of three mass killers and one would-be mass killer, concluding that they all appeared to have suffered from an intense form of paranoia: "The paranoid individual is obsessed with revenge and justifies the revenge as payback for a perceived injustice," the researchers write. "(Such people are) thin-skinned or hypersensitive to perceived slights (and they) have closed information-processing systems that preclude corrective information which is inconsistent with their world view from being received." This condition, left untreated, can have tragic consequences for others.
See also Lynne Forrest's work on the Drama Triangle where Ms Forrest postulates that people with a victim mentality occupy and move between roles of persecutor, rescuer and victim. She has developed an interpretation of the Karpman Drama Triangle, which she calls the "Victim Triangle" and which she uses to demonstrate how a person with victim mentality can switch between their starting roles of Victim, Persecutor and Rescuer. She believes that those who start out as Rescuers see themselves as "helpers" and "caretakers", needing someone to rescue in order to feel vital and important. Persecutors, on the other hand, identify themselves primarily as victims, in complete denial about their blaming tactics. People who begin as Victims eventually retaliate and, in doing so progress to the role of Persecutor, maybe even switching roles with their Persecutor, who now becomes a Victim. Without a conscious desire to change, some people never leave these roles.
Attention seeking and narcissism
Narcissism occurs to different degrees in different people and it's more prevalent among business leaders than in the wider population. When it gets out of control, the short-term benefits to the business are outweighed by long-term unsustainability which can and often do lead to disaster.
Tim Field noted that in the charity / voluntary / not-for-profit sector, in most cases a serial bully was identified as a female, whose objective was to demonstrate to the world what a wonderful, kind, caring, compassionate person she was, making bold pronouncements, a prominent position, gushing empathy, sitting on many committees for good causes, etc. However, staff turnover was often high and morale low amongst those doing the work and interacting with clients. In each case, the relief of others' suffering changed from being an objective into a vehicle for gaining attention. In some situations, more money was spent the consequences of the serial bully's behaviour than was spent on clients. See case histories #1 and #3 and #10 for typical examples.
A selection of books about bullying, bullies, difficult behaviour, stress and survival strategies
About Older Articles
Related Matters
Tim Field
Tim Field Foundation
Copying from this Website
Bullyonline.org was started in 1996 by the late Dr Tim Field and is now maintained by the Tim Field Foundation, Charitable Incorporated Organisation reg no. 1162273


DMMS receives Gold Ribbon Award for outstanding Dance Program.
Questions about what shots your student needs?
These resources provided may assist students, parents and staff with stressful situations and how to deal with them personnally and in the classroom.
Check out what is happening at DMMS, MVUSD and the Community with our E-Flyers from Peachjar.
Check Your Points on 5 Star!!!


Your Emotional Balance is something that keeps up in check for our emotional energy flow within our energy fields. Have you been feeling a bit off balance with your emotional status? Do you seem to shift emotions very quickly; from happy to anger or calm to frustrated? Emotional instabilities can occur within your energy fields due to energy leakage, blockages, or stagnant energy. They can cause the energy to pool and spin out of control. This can affect your moods, mental clarity, emotional issues, spiritual problems, chakra issues, meridian blockages, aura stability, and much more.
When we are speaking on an emotional balance, this is not when you happen to have an off day once in a while, as this could just be a mood shift or other energetic shift that you are experiencing. We are talking about that balance that is from within and is with you day in and day out. An emotional balance issue is something that you deal with every day in your life, not just the occasional off day, as this is something that many people feel control's their lives. You do not have to be a victim to this imbalance any longer, as there is help on an energetic level that can shift this into the positive and bring balance and harmony back to these energy patterns!
Emotional Balancing is about those instabilities that you see in your daily life, that gut feeling when you know there are issues that you need to work on, and those times when you have to take back control of your life and your emotional side. These issues are things that need to be worked on through an energetic level to re-stabilize the emotional areas on your energetic fields. Once they have been re-stabilized within these areas than the energy patterns can flow as they should and the result is a balanced and high functioning free flowing energy pattern!
An Emotional Balancing Session removes all of the problem areas after a scan has been completed to see the issues. Once this has been completed, all areas are healed, sealed, and the energy issues are corrected to complete a fluid energy flow to balance the energetic frequencies to a harmonious state. This will cause the shift within your physical, emotional, mental, and spiritual level so that they will be balanced again. When receiving an Emotional Balance Healing session make sure to focus on the positive issues at hand, relax and be in a receptive state of mind. Ms. Lanning will connect in with your energy fields for the session to be completed and an integration protection is placed after all of the work that has been done. The energy shifts will have a positive energetic flow for your energy patterns and a balance from within for your healing process. This session takes 2 hours to complete.